Rhabdomyosarcoma New Diagnosis
Rhabdomyosarcoma New Diagnosis
ARST2032: Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
- Ages: Up to 21 Years
Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues in the body. This phase III trial aims to maintain excellent outcomes in patients with very low risk rhabdomyosarcoma (VLR-RMS) while decreasing the burden of therapy using treatment with 24 weeks of vincristine and dactinomycin (V ...More
FAPI-1301: 64Cu-LNTH-1363S in Patients with Sarcoma or Gastrointestinal Tract Cancer (PHANTOM)
- Ages: 18 Years and older
This is a multicenter, open-label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity and mass dose) and imaging time window of 64Cu-LNTH-1363S (64Cu Radiolabeled FAPi PET/CT Imaging Agent) and to compare its ima ...More
Contact Us
To learn more about available sarcoma clinical trials, contact us at cancer@cchmc.org or 513-636-2799.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2025 Cincinnati Children's Hospital Medical Center. All rights reserved.
